Transactions

  • Specialism

  • Lifecycle Stage

GNX 12: Getting your voice heard by big pharma

GNX 11: Using Independent Expert Reports for an IPO

GNX 10: Transactions – Good Practice Part II

GNX 9: Transactions – Good Practice Part I

GNX 8: The Divestment Challenge

GNX 7: PharmaVentures Data Room Structure Guideline

GNX 5: M&A in COVID-19 Environment and Beyond – Keep Your Perspective

GNX 6: Why Licensing and Partnering Activity Should Remain Steady in 2020

GNX 4: Partnering Essentials: Identifying and Engaging with Potential Licensees

GNX 3: Will the latest diagnostic technologies change clinical practice?

GNX 2: Interpreting and Negotiating Deal Terms for a Licensing Agreement

GNX 1: Dancing with the Dragon: Cross-border Transactions between China and the World

GNT 50: Retention of Losses Post Merger

GNT 39: Demergers

GNT 21: Tax Efficient Divestment

GNT 20: Substantial Shareholdings Exemption

GNT 4: Deferred Consideration

GNT 3: Licensing

Sign-Up For Free

Sign-up to receive up-to-date information and advice on tax developments within your industry.

Sign-up for free